Last update Feb. 11, 2025
Decreased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary., is now set to Safe product and/or breastfeeding is the best option.
Level of risk reviewed on Feb. 11, 2025
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Clopidogrel is also known as
Clopidogrel in other languages or writings:
Clopidogrel belongs to this group or family:
Main tradenames from several countries containing Clopidogrel in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | < 50 | % |
Molecular weight | 322 | daltons |
Protein Binding | 98 | % |
VD | 0.56 ± 0.48 | l/Kg |
pKa | 5.14 | - |
Tmax | 1.4 ± 1.1 | hours |
T½ | 6 | hours |
Relative Dose | 0.008 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Platelet antiplatelet indicated in the secondary prevention of thromboembolic events (after myocardial or cerebral infarction), coronary syndrome and atrial fibrillation. Oral administration as a single daily dose. (EMA 2018)
It is excreted in breast milk in negligible amounts. (Van Neste 2024)
In addition, its low oral bioavailability hinders passage into infant plasma from ingested breast milk, except in premature infants and immediate neonatal period where there may be increased intestinal permeability.
No adverse effects in infants have been observed with maternal use of clopidogrel during breastfeeding in a small number of post-marketing cases (ScieGen2023). One infant had clinically insignificant plasma levels and two infants aged 7 and 14 months had no problems. (Van Neste 2024)
It has been used with good tolerance in pediatrics even in newborns and infants. (Li 2008, Finkelstein 2005)
The manufacturer and various experts consider the use of this medication during breastfeeding to be probably compatible if an alternative cannot be chosen. (LactMed, ScieGen 2023, Briggs 2017, Hale 2019 p 167, Rowe 2013)
Risk can be minimized by waiting to resume breastfeeding, if possible, a minimum of 6 hours after the last intake of the drug.
Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Serrano 2015, Bell 2011), especially during the neonatal period and in case of prematurity.